Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Biotechnology

Health Care

Therapeutics

Asceneuron

Asceneuron's headquarters in Lausanne, Switzerland

Barbara Angehrn Pavik

Ryan Schubert

Colin Kahrs

Ruhi Ahmed

Sandra Millet

Peter Van Vlasselaer

Deborah Harland

Lior Teitelbaum

Eric Yuen

Henrijette Richter

Hakan Goker

Adam Boxer

Christian Haass

Günter U. Höglinger

Raymond G. Hill

The Scientific and Clinical Development team at Asceneuron is responsible for advancing therapeutic candidates from preclinical stages through early clinical trials. This includes developing translational medicine strategies, overseeing preclinical development, assessing ADME (absorption, distribution, metabolism, and excretion) and toxicology, and guiding non-clinical development and medicinal chemistry efforts. Their ultimate goal is to ensure the safety, efficacy, and regulatory approval of novel treatments for orphan tauopathies and Alzheimer’s disease.

Scientific and Clinical Development

The Leadership Team at Asceneuron is responsible for guiding the strategic direction and oversight of the company's initiatives. Key members, including the SVP of Translational Medicine & Clinical Strategy, VP & Head of Clinical Development, and SVP & Head of Regulatory Affairs, collaborate to advance clinical programs, regulatory compliance, and overall therapeutic development for orphan tauopathies and Alzheimer’s disease.

Leadership Team

Asceneuron

Org chart

Board & advisors

Teams

Scientific and Clinical Development

Leadership Team

Offices

Asceneuron

Org chart

Board & advisors

Teams

Scientific and Clinical Development

Leadership Team

Offices

Related companies